 Additional Growth Driver Projected to Significantly Increase Mid-to-Long Term Revenue Potential REDWOOD CITY, Calif., Jan. 09, 2023 GLOBE NEWSWIRE Coherus BioSciences, Inc. Coherus or Coherus BioSciences, Nasdaq: CHRS announced today that it has executed a binding term sheet with Klinge Biopharma GmbH Klinge Biopharma for the exclusive commercialization rights to FYB203, a biosimilar candidate ... The post Coherus Agrees to Acquire Exclusive U.S. Commercial Rights to Eylea Biosimilar FY... 